title: Combined lycopene and vitamin E treatment suppresses the growth of PC-346C human prostate cancer cells in nude mice.
abstract: Epidemiologic studies have repeatedly associated a high intake of lycopene and vitamin E with reduced prostate cancer risk. The present study examined the ability of the 2 compounds to reduce tumor growth and prostate-specific antigen (PSA) plasma levels in the PC-346C orthotopic mouse model of human prostate cancer. Three days after intraprostatic tumor injection, NMRI nu/nu mice were administered a daily oral dose of synthetic lycopene [5 or 50 mg/kg body weight (BW)], vitamin E in the form of alpha-tocopheryl acetate (5 or 50 mg/kg BW), a mixture of lycopene and vitamin E (5 mg/kg BW each), or vehicle. Intraprostatic tumor volume and plasma PSA concentrations were measured at regular intervals. Mice were killed when the tumor load exceeded 1000 mm(3) or on d 95 when the study was terminated. Prostate and liver were analyzed by HPLC for lycopene isomers and alpha- and gamma, delta-tocopherol concentrations. None of the single treatments significantly reduced tumor volume. In contrast, combined treatment with lycopene and vitamin E, at 5 mg/kg BW each, suppressed orthotopic growth of PC-346C prostate tumors by 73% at d 42 (P < 0.05) and increased median survival time by 40% from 47 to 66 d (P = 0.02). The PSA index (PSA:tumor volume ratio) did not differ between experimental groups, indicating that PSA levels were not selectively affected. Lycopene was detected only in mice supplemented with lycopene. As in humans, most tissue lycopene was in the cis-isomer conformation, whereas 77% trans-lycopene was used in the dosing material. Liver alpha-tocopherol concentrations were increased in mice supplemented with both 50 mg/kg (226%, P < 0.05) and 5 mg/kg vitamin E (41%, P < 0.05), whereas prostate alpha-tocopherol concentrations were increased only by the higher dose (83%, P < 0.05). Our data provide evidence that lycopene combined with vitamin E may inhibit the growth of prostate cancer and that PSA can serve as a biomarker of tumor response for this treatment regimen.
authors.affiliation: Department of Urology, Erasmus MC, Rotterdam, The Netherlands.
authors.forename: Jacqueline
authors.initials: J
authors.lastname: Limpens
authors.forename: Fritz H
authors.initials: FH
authors.lastname: Schröder
authors.forename: Corrina M A
authors.initials: CM
authors.lastname: de Ridder
authors.forename: Cindy A
authors.initials: CA
authors.lastname: Bolder
authors.forename: Mark F
authors.initials: MF
authors.lastname: Wildhagen
authors.forename: Ute C
authors.initials: UC
authors.lastname: Obermüller-Jevic
authors.forename: Klaus
authors.initials: K
authors.lastname: Krämer
authors.forename: Wytske M
authors.initials: WM
authors.lastname: van Weerden
mesh_terms: D000818:Animals; D016588:Anticarcinogenic Agents / Q000494:pharmacology*; D002338:Carotenoids / Q000008:administration & dosage / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D019587:Dietary Supplements; D006801:Humans; D000077276:Lycopene; D008297:Male; D051379:Mice; D008819:Mice, Nude; D011471:Prostatic Neoplasms / Q000473:pathology*; D014183:Transplantation, Heterologous; D014810:Vitamin E / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D016588:Anticarcinogenic Agents; D014810:Vitamin E; D002338:Carotenoids; D000077276:Lycopene